ABIVAX Société Anonyme (BATS-CHIXE:ABVXp) - Aandelenkoers, Nieuws & Analyse

ABVXp Overzicht aandelen

A clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. Meer informatie

ABVXp fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 54.33% per jaar groeien

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 19.1% per jaar dalen.

Heeft een omzet van minder dan 1 miljoen USD ( €20K )

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Aandelen zijn zeer illiquide

+ 1 meer risico

ABIVAX Société Anonyme Concurrenten

Avacta Group

AIM:AVCT

UK£182.9m

Oxford Biomedica

LSE:OXB

UK£447.3m

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£195.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor ABIVAX Société Anonyme
Historische aandelenkoersen
Huidige aandelenkoers	€16.22
52 Week Hoogtepunt	€16.50
52 Week Laag	€6.01
Bèta	1.32
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	110.10%
33 jaar verandering	-26.10%
5 jaar verandering	46.65%
Verandering sinds IPO	-21.57%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	ABVXp	GB Biotechs	GB Markt
7D	0%	1.5%	2.2%
1Y	110.1%	-17.9%	8.8%

Rendement versus industrie: ABVXp overtrof de UK Biotechs industrie, die het afgelopen jaar een rendement -17.9 % opleverde.

Rendement versus markt: ABVXp overtrof de UK markt, die het afgelopen jaar een rendement opleverde van 8.8 %.

Prijsvolatiliteit

Is ABVXp's price volatile compared to industry and market?
ABVXp volatility
ABVXp Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: ABVXp heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van ABVXp in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	26	Marc M. de Garidel	www.abivax.com

ABIVAX Société Anonyme Samenvatting

Hoe verhouden de winst en inkomsten van ABIVAX Société Anonyme zich tot de beurswaarde?
ABVXp fundamentele statistieken
Marktkapitalisatie	€602.03m
Inkomsten(TTM)	-€91.51m
Inkomsten(TTM)	€20.00k

Over9,999x

P/S-verhouding

-6.6x

Koers/Winstverhouding

Is ABVXp overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ABVXp resultatenrekening (TTM)
Inkomsten	€20.00k
Kosten van inkomsten	€0
Brutowinst	€20.00k
Overige uitgaven	€91.53m
Inkomsten	-€91.51m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.46
Brutomarge	100.00%
Nettowinstmarge	-457,550.00%
Schuld/Eigen Vermogen Verhouding	50.1%

Hoe presteerde ABVXp op de lange termijn?

Bekijk historische prestaties en vergelijking

ABVXp Overzicht aandelen

Beloningen

Risicoanalyse

ABIVAX Société Anonyme Concurrenten

AIM:AVCT

UK£182.9m

LSE:OXB

UK£447.3m

LSE:GNS

UK£1.1b

AIM:BVXP

UK£195.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

Recent updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Forecast breakeven date moved forward to 2022

Insufficient new directors

Insufficient new directors

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Forecast to breakeven in 2024

Insufficient new directors

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Insufficient new directors

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

New 90-day high: €28.90

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

ABIVAX Société Anonyme Samenvatting

Over9,999x

-6.6x

Inkomsten en omzet